Less Talk, More Action

Eradicating forced labor and ending modern slavery is a target of the UN’s Sustainable Development Goal number eight: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all.

Human Rights Violations are the result of a few factors:

The risk of forced labor in global supply chains remains one of the most significant human rights issues for companies and their investors. At least 25 million people are currently estimated to be victims of forced labor in supply chains supporting many of the world’s favorite brands.

Awareness on these issues continues to grow since the Rana Plaza tragedy in 2013, as dissemination of information regarding supply chain practices becomes more accessible thanks to the global digital age. Consumers, advocacy groups, and governments are increasingly demanding transparency, accountability, and ethical practices in supply chains. However, tangible progress from corporations is sporadic. Many firms have formally pledged to enhance their supply chain oversight, but these commitments rarely translate into substantive change. This gap between promise and practice is starkly illustrated by a December 2023 study that shed light on 39 European clothing brands (including Prada, Levi’s and Inditex), at probability of using Uyghur forced labor in their supply chains. This is far from being the first report on the topic: issues of forced labor of the detained Uyghur population in China’s Xinjiang region, and its presence in supply chains of major companies have been known since 2009!

A significant percentage of companies assessed by the Corporate Human Rights Benchmark claim high standards for supplier conduct, with 85% stating prioritizing human rights in their supplier contracts. However, there is a clear shortfall in transparency and practical support. Only 27% of these companies offer evidence of aiding their suppliers in upholding these human rights standards, indicating a disconnect between stated policies and actions fostering responsible supply chains. Additionally, the Fashion Transparency Index reveals that none of the companies it has assessed have fully disclosed their first or second-tier supplier lists.

Moreover, placing the responsibility for upholding human rights solely on suppliers risks falling short of objectives to create decent work for all. Improvements like reduced overtime and on-site healthcare in factories, frequently showcased during audits, are often not maintained. Companies operating in Asian countries often lack a thorough understanding of their supply chains, making it challenging to ensure they are not involved in human rights abuses. Western companies seeking to verify the integrity of their suppliers in Xinjiang face potential backlash from the Chinese government.

This persists despite company claims that they are responding to the issue.

The Regulatory Mirage

Understanding the gaps between corporate promises and supply chain realities means examining regulatory responses. The table below highlights many recent regulations in various jurisdictions that aim to transform voluntary principles into enforceable laws. The impact of these new regulations is highly uncertain due to the challenges of interpreting supply chain disclosures. Regulations tend to expand disclosure requirements, but can result in a deluge of data that investors find challenging to navigate. Moreover, regulations frequently lack a clear mandate for companies to take concrete corrective actions.

Unfortunately, recent regulations have not always been effective in preventing violations. A high-profile example occurred in 2020: despite the UK Modern Slavery Act being in effect, fashion retailer Boohoo came under intense scrutiny for perpetuating modern slavery conditions within its supply chain. Reports emerged detailing workers in Leicester's garment factories, which supplied Boohoo, being paid significantly below the minimum wage, with some wages as low as £3.50 an hour, alongside working in unsafe and exploitative conditions. The repercussions were immediate and severe for Boohoo. Following these allegations, Boohoo's share price fell by more than 20% in two days after major online retailers such as ASOS, Zalando, and Next dropped the brand from their platforms. It ultimately wiped £1.1bn off the value of the business.

As for the consequences of non-compliance, companies may face substantial fines. Under the proposed Corporate Sustainability Due Diligence Directive (CSDDD) in the EU, whether such sanctions truly deter companies may hinge on the level of enforcement by member states. It remains to be seen whether this will have a significant impact on corporate behavior. ​

 

Unveiling Delusions

Moving beyond regulatory efforts, it is crucial to consider the interplay of corporate advocacy and accountability. Some entities actively lobby against more stringent measures designed to ensure accountability and protect human rights. These tactics highlight the tension between corporate interests and the push for greater corporate responsibility.

There is further evidence of this disconnect in stakeholder actions, where companies’ ethical commitments are questioned - yet go un-penalized in the market. The following table examines the market's response—or lack thereof—to significant human rights controversies involving major corporations.

The observed market data underscores a concerning trend: stock prices remain largely unaffected by the disclosure of human rights violations. This indifference signals a disconnect between ethical corporate behavior and financial consequences, indicating the market's challenges in serving as a corrective force. Boohoo's stock decline, as stated above, was an exception, attributed to the company’s lack of Human Rights Due Diligence (HRDD) systems. This contrasts sharply with other industry giants, which have purportedly demonstrated commitment through the implementation of more effective HRDD systems.

 

The Investor as a Catalyst

As an investor committed to responsibility, it is crucial to understand that regulatory measures alone are currently insufficient and market responses can be unpredictable. Human rights concerns, while recognized, are not yet a priority for the majority of investors.

This highlights an opportunity for investors to lead the way in elevating human rights. It is crucial for investors to conduct thorough research. Frameworks exist to guide investors in this path.

The OECD Human Rights Due Diligence (HRDD) framework guides companies in identifying, preventing, and mitigating their impacts on human rights throughout their operations and supply chains. The framework offers a structured approach to assess risks, integrate responsible practices, track progress, and communicate actions, aligning business conduct with international human rights standards, as shown in the chart below.

While the HRDD Guidance is designed for companies to ensure responsible business conduct, these key principles are equally critical for investors to apply in their assessment and engagement strategies.

To operationalize these principles, there are a variety of tools investors can access. However, investors must be cautious when navigating these resources as some have faced recent controversies. One such example is the Higg Index, a system developed by major fashion brands to gauge environmental impact. This tool has been criticized for favorably rating synthetic materials, derived from fossil fuels, over natural ones. Critics argue that some of the underlying data is industry-funded and not fully open to independent verification, potentially misleading consumers about the sustainability of products.

Acknowledging these complexities, we have compiled a list of our top tools and resources for investors’ evaluation of human rights practices.

Investors can also play a role in advocating for human rights through proxy voting and shareholder proposals. Recent trends show progress in this area. In 2023, the number of shareholder proposals in the U.S. on human rights saw an uptick to 37 (compared to 16 in 2022). Despite typically not gaining majority support, average approval rates have improved, reaching a median support of 31.4% (compared to a 24% median support between 2020 and 2022). This signals growing acknowledgment of human rights issues in corporate governance. Investors leveraging these mechanisms are contributing to a heightened corporate focus on human rights matters.

Temporary employment is a well-known leading indicator of job market health. Temp agencies – with their ability to quickly instate and terminate short-term contracts – give an excellent lead on the overall health of the job market (see the chart of U.S. data below). Already, temp agencies have seen a marked slowdown in the number of worker placements, a sign of what’s likely to come for the overall job market.

Many of the major players in the temp staffing industry had a fantastic stock price performance from late 2020 to spring 2022. However, these companies did not participate in the 2023 tech-led bull market; the top four temp agencies all posted negative stock price returns in 2023.  This seems appropriate, given that profits at these companies are positively correlated with employment growth (and overall economic growth). 

Indeed as Manpower - a major staffing company - explained in it’s most recent annual report, “improving economic growth typically results in increasing demand for labor, resulting in greater demand for workforce solutions and staffing services…During periods of increasing demand, we are generally able to improve our profitability and operating leverage as our cost base can support some increase in business without a similar increase in selling and administrative expenses…When demand drops, our operating profit is typically impacted unfavorably as we experience a deleveraging of our selling and administrative expense base as expenses may not decline at the same pace as revenues.”

Judging by the magnitude of previous employment cycles, it is reasonable to expect that staffing companies are likely to see further slowdown in the demand for their services, and hence their stock prices. Investors concerned with sustainability need to be extremely discerning in the staffing sector as many of these companies have nefarious compensation schemes and neglect to report on material activities.

In today’s note, given the unfavorable macro prospects for this sector, we concentrate primarily on short-selling opportunities in companies that have adverse practices.

Note that most countries have some form of temporary labor market where staffing agencies act as the middleman between prospective employers and employees, but the reliance on temporary workers varies significantly. In the U.S., temp work currently accounts for only 2% of recorded employment, whereas in the euro area, it accounts for over 17%. Some of the gap is due to measurement differences but it is mainly due to the fact that European employers typically must pay greater severance and face great restrictions on firing permanent employees; an incentive for European employers to hire workers on temporary contracts when possible. That said, in the U.S. there is far less regulation of temp workers, and no limit on duration or guarantee of equal treatment. Ergo, for the 2% of temp workers in the U.S., the stakes are far higher.

Part One: The Issues With Temp Staffing Agencies

Sustainable Market Strategies’ Labor Fairness investment theme focuses on competitive wage practices, skills training, and generous benefits and health insurance. These characteristics identify quality employers that in turn face lower employee turnover rates and risk of strike disruption.

Staffing agencies can theoretically fit this bill and have an important role in the labor market. After all, agencies facilitate access to employment across a myriad of industries. In some countries, notably the euro area, temporary staffing is a well-regulated industry with limited discrepancies between temporary and permanent staff. However, this is not the case in markets like the U.S. and Canada. In stark contrast to material labor topics included in the SASB framework, temp workers face issues of unfair compensation, inadequate health and safety training and discrimination.  The U.S. industry of temporary staffing in particular is clearly in need of an overhaul with laggards being the most at risk from a tighter labor market or a policy change. The Restoring Worker Power Act (tabled in 2020 but not passed before the end of the congressional session) would have required equal pay for equal work, stronger data disclosure from staffing agencies including conversion to permanent positions, race and gender diversity.

Focusing on temp workers in the U.S., a survey of over 1300 such workers showed 24% of respondents had experienced issues of receiving pay below the minimum wage, failing to be paid for overtime or the total number of hours worked. Incredibly, 35% of those surveyed held their current position for over a year, and 18% had at least a two-year tenure! A comparison of the median wages for temp workers versus total employees by industry illustrates how temp workers are getting paid less for similar jobs.  

In addition to pay inequality, there is also evidence of a lack of proper training as well as instances of discrimination at staffing agencies. Inadequate training is especially precarious in higher risk industries like construction, warehousing and manufacturing where temp worker are twice as likely to be injured on the job. While temporary staffing could be seen as a positive for minority groups (black and Latinx are overrepresented in the temporary workforce), low-quality jobs – characterized by the poorest working conditions, sometimes termed “low road” employment - are assigned to Black and Latinx persons at a higher rate.

Part Two: How The Main Companies Stack Up

We looked at the largest (by market cap) staffing services companies in Europe and North America. From a sustainability perspective, it is challenging to find quality disclosures on temporary workers in the company reporting of staffing agencies. Indeed, CSRHub scores on reporting and transparency are generally weak across the sector, underscoring that these companies are poor at reporting on material topics. With the exception of ManPower Group, none of the companies report on the number of contract workers in accordance with the SASB disclosure topic or provide any relevant SASB metric.

Given the lack of reporting based on SASB, we use CSRHub scores that align with material topics in the staffing services industry to gauge the sustainability of staffing companies. Note that CSRHub scores may be artificially inflated by disclosures that are based only on direct employees and not the temp workers they are placing.  CSRhub scores related to compensation stand out as especially weak, likely a reflection the occupational data shown in the previous table: staffing agencies provide inferior wages to temporary employees.

 

Note that all four of the large staffing companies draw the majority of their revenues from placing temporary workers, while consulting and permanent placements (i.e. jobs with less pay discrepancy) account for only a small share of their business.

Overall, the adage that “staffing agencies work for the employer not the employee” appears to ring true. While these companies fulfill the function of matching job seekers to employers (thus decreasing friction times in the labor market), their business model is built on offering below-market compensation to workers; these companies make good potential short candidates within sustainable investment portfolios.

In the table below, we provide the financial characteristics of our sample companies. Some points stand out:

As the sustainable investing industry continues to mature, participants seek investment opportunities in themes beyond climate change and renewable energy. One of the increasingly popular themes in the social investing space is financial inclusion.

Far be it from us to pretend that this topic is new – we have written several notes on this subject, including “Banking on Impact” on August 31, 2023, and “Three (Sexy) Banking Plays to Change the World” on September 8, 2022.

It’s time to re-visit this subject given inclusion of some of these companies in supposed “impact” funds that has us raising our collective eyebrows.

The increase in popularity of the financial participation theme also entices some companies to try to brand themselves with the “financial inclusion” label, knowing it could attract investors. This is another form of greenwashing – this time the green is for the color of the money!

Take the recent story involving a Nasdaq-listed company called Tingo Group and Agri-Fintech Securities (TIO US). For years, it defrauded investors on the basis that it was providing financial products and services to millions of Nigerian farmers. Tingo was even included in a handful of Article 8 and 9 funds on that basis. Following a report by the US-based short seller Hindenburg Research last year, the SEC recently concluded that Tingo inflated its accounts with ‘billions of dollars of fictitious transactions’ and was in fact an empty shell with no products and even fewer clients.

However, when done right, financial inclusion can be a significantly impactful sector. After all, there is a growing recognition of the importance of financial inclusion as a catalyst for sustainable development. Governments, financial institutions, and international organizations are increasingly focusing on strategies to expand access to financial services as it is positioned prominently as an SDG enabler; it is featured as a target in eight of the seventeen Sustainable Development Goals, with notable positive impact on gender equality, poverty, health and education.

The latest iteration of the World Bank's Global Findex, a comprehensive survey conducted every three years to assess the state of financial inclusion worldwide, reveals a startling reality: nearly a quarter of the global population is without a formal bank account. This basic financial service is a cornerstone of financial inclusion, yet access to it is uneven across different demographics, influenced by factors such as nationality, gender, income levels, and educational background. Thankfully, mobile money accounts are rapidly becoming an alternative to traditional banking in the developing world.

The goal of achieving universal financial inclusion is not only about providing financial services but also about creating a financial system that will improve the socio-economic conditions of the underserved and undervalued populations.

Yet, it seems that some portfolio managers are quick to put in the “financial inclusion” bucket pretty much any company that operates in the financial or fintech sectors and that serves populations in developing countries.

Let’s use three company examples active in South America that are often found in various forms of impact funds: dLocal (DLO US), Nu Holdings (NU US) and MercadoLibre (MELI US).

On the surface, dLocal could be attractive for investors who care about financial inclusion. They are a pure play fintech company operating out of Uruguay and Brazil and derive more than 90% of their revenues almost exclusively from emerging and frontier markets. But behind the financial inclusion buzzwords, they operate a payment platform that, in a nutshell, facilitates transactions between the largest tech firms (Amazon, Google, Uber, etc.) and customers that are underserved by mainstream payment providers such as Visa or MasterCard. Moreover, they charge above-market fees (up to 7%) for that service. The social impact is minimal and dLocal would be a questionable name to include in an impact fund.

Nu Holdings, or Nubank as it is commercially known, has a slightly better financial inclusion story, but we are still not completely convinced the company is making a substantial impact. True, Nubank brought six million Brazilians into the financial system for the first time by allowing them to open a digital bank account in just a few steps. This is undoubtedly good. But beyond that financial inclusion story – which is what they want you to know about them – they derive the vast majority of their revenues from the remaining 70 million clients they serve. Much like other consumer finance companies, the main way they generate revenues is via fees and interests paid on loans. For Nubank though, 80% of the interest paid to them come from their credit card segment, which charges up to 20% a month in interest fees, or up to 200% a year! While this is in line with other Brazilian financial institutions, generating this much revenue from credit card loans as opposed to more socially productive personal or business loans hurts their financial inclusion credibility. Though not entirely convinced, we understand why some managers include this name in the financial inclusion theme.

The case for impact investing is easier when it comes to MercadoLibre, which is Latin America’s largest ecommerce platform and emerging as a leader in the region’s financial technology (fintech) industry. In 2021, the firm served 51.5 million individual fintech customers. Additionally, 900,000 households identified MercadoLibre’s platform as their primary income source. On average, the platform was responsible for the creation of 6 jobs every hour. Throughout the year, more than half a million small-to-medium enterprises (SMEs) utilized the platform for sales. The company has a net positive impact through its democratisation of commerce and financial services. It aims to level the playing field between large and small vendors, and to make payments and commerce processes simpler, safer and more efficient for all.

The U.S. healthcare system is distinct from other developed economies, marked by its absence of universal coverage and a complex mix of private and public elements. This makes healthcare accessibility and affordability ongoing national challenges and also presents important opportunities and risks for sustainability investors. After all, the enjoyment of the highest attainable standard of health is considered a fundamental human right.

America’s Dysfunctional Healthcare System

Despite spending the most on healthcare compared to other rich countries, as illustrated in the chart below, the U.S. has worse outcomes for metrics such as life expectancy, avoidable hospital stays, suicides, and maternal mortality.

About 65% of Americans rely on private health insurance, but the quality and cost of coverage is extremely heterogeneous. Moreover, nearly 26 million American (8% of the population) are uninsured or underinsured. The table below provides a snapshot of health coverage distribution in the U.S. 

This discrepancy in coverage is further exacerbated by the U.S.’ complex drug pricing system. The U.S. healthcare system is characterized by its limited capacity for insurers to effectively negotiate drug prices, in stark contrast with nations like Germany where government-led negotiations help maintain cost controls. This disparity in bargaining strength contributes to higher medication costs in the U.S. The chart below shows the complex journey of how drugs are priced, involving many players including consumers, pharmacies, wholesalers, and manufacturers.

Insurers, through negotiated payments and rebates with Pharmacy Benefit Managers (PBMs) and drug manufacturers, struggle within a system that favors opaque transactions and inhibits straightforward price bargaining. This visual representation underscores the critical vulnerability in how the U.S. manages prescription drug pricing, driven by market dynamics rather than patient need and health outcomes.

In the face of such complexity, costs for crucial medications like insulin have soared, as we discussed in the note “Basic Instinct: The Insulin Profit Machine” (September 22, 2022). These costs are born by those with private insurance and also by public healthcare programs.  

 

The Patchwork of Public Healthcare

In a system with no universal coverage and high drug prices, government initiatives like Medicare and Medicaid play a vital role, offering an alternative to private insurance to more vulnerable populations. Established in 1965, Medicare provides health insurance for those aged 65 and older, while Medicaid caters to people with limited income; both are funded through taxes from employees and employers.

Medicare, comprising Part A (hospital insurance), Part B (medical insurance), Part C (advantage plans) and Part D (prescription drug coverage), cover most healthcare services, but not all, with the costs partially shared by the insured. This cost-sharing structure underscores the critical role of these programs, especially since there has been a steady increase in the share of Americans covered by Medicare and Medicaid (see chart below).

 

The increase in Medicare beneficiaries coincides with an ageing population, which is leading to exploding costs, projected in the following chart:

It is notable that in 2010, the Affordable Care Act (ACA) was the first major regulatory change to Medicare and Medicaid. The aim of the ACA was to expand coverage and was successful at eliminating some coverage gaps, although 8% of the population still remain uninsured. What’s more, these efforts, while critical in expanding access, came with substantial fiscal implications for the government: in 2021, Medicare spending comprised 13% of the federal budget and 21% of national healthcare spending.

 

Next Battle: Addressing Drug Prices

The next battle for improving the U.S. healthcare system involves tackling high drug prices. The Biden administration campaigned on a promise to lower the cost of prescription drugs and intends to make lowering healthcare costs a theme of the 2024 re-election campaign. This follows on its initial tackling of prescription drug prices in the Inflation Reduction Act of 2022. The act includes provisions to lower prescription drug costs for Medicare beneficiaries and to reduce federal drug spending. A notable aspect of this legislation is the cap on insulin costs at $35 per month for seniors on Medicare since January 2023.

Following this legislative change, Eli Lilly and Novo Nordisk – major producers of insulin - announced in early 2023 significant price reductions and expanded accessibility programs. Eli Lilly announced reducing prices for key insulin, impacting 10.5% of its U.S. revenue, and the expansion of its Insulin Value Program (that caps out-of-pocket costs at $35 per month). Novo Nordisk's price cuts, effective for several of their insulin products, will influence 59% of their insulin sales in the U.S. Despite these changes, advocacy groups like T1International demand further reductions, highlighting the significant gap between production costs and retail prices.

In a broader context, the IRA mandates the federal government to negotiate prices for select high-expenditure drugs covered under Medicare Part B and Part D, starting in 2026. This measure aims to put downward pressure on Part D premiums and out-of-pocket costs for Medicare beneficiaries. The program is projected to save $98.5 billion over ten years, although the pharmaceutical industry cautions that it might deter the development of new drugs,. The Congressional Budget Office (CBO) projects that the impact of these provisions on the introduction of new drugs to the U.S. market will be very modest (i.e. a potential reduction of 1% over the next 30 years, which translates to about 13 fewer drugs out of an estimated 1,300 new drugs. In other words, the Act offers solutions to control costs while expanding coverage, without stifling pharmaceutical innovation.

The Medicare drug price negotiation process targets high-cost drugs, with the inaugural selection representing 20% of Part D costs, or $50.5 billion, from mid-2022 to mid-2023. These drugs are produced by major pharmaceutical companies, and often account for a significant share of their revenue (see table below).

Following the U.S. government's announcement about Medicare drug list for price negotiations at the end of August, AbbVie disclosed a $2.1 billion charge in anticipation of reduced revenue from its cancer drug Imbruvica. Six pharmaceutical manufacturers—Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson and Merck—took the Biden administration to court in an attempt to block the negotiation program, but finally agreed in early October to negotiate drug prices with the government.

Pharma Under Pressure

Since the IRA was announced, the performance of U.S. big pharma stocks has lagged the broader S&P 500 Index. Removing the effect of the largest tech companies and using the equal-weight S&P 500 index (the latter corrects for the massive performance bias of the Magnificent 7) shows U.S. big pharma stocks have slightly outperformed. However, within U.S. big pharma, Eli Lilly has been the star performer, up 96% during the period, primarily due to the obesity drug craze (see note “You Can Have Your Cake and Eat it Too” from November 16, 2023). The rest of U.S. big pharma have underperformed by a substantial margin (as seen in the chart below). We believe that government regulation is hanging a dark cloud over the industry and is affecting industry performance, just another example of how fiscal policy and regulation influence market performance in the current era.

With only the initial phase of negotiations underway, there is potential for further impact on other major pharmaceutical companies in the subsequent rounds, with ultimately 60 drugs to be affected between 2026 and 2029. Of course, this is highly dependent on the outcome of the 2024 election; Republicans are not in favor of interventionist pricing.

The table below highlights the drugs (and the companies producing them) that represent the highest costs in Medicare Part D, as of 2021, which could potentially be implicated in future Medicare negotiations.

 

Overall, the IRA represents a serious government effort to address high prescription drug costs in the United States. While the Medicare drug price negotiations specifically target costs for government-funded healthcare, there is potential for a ripple effect that could lead to broader price reductions if negotiations set new benchmarks for drug pricing. This could have a meaningful impact on pharmaceutical companies.

“Wegovy” and “Ozempic” have become household names in the blink of an eye: in 2023, the number of prescriptions for these anti-obesity medicines exploded, bringing with it a surge in hope that one major public health concern can finally be tamed. After all, obesity contributes significantly to the burden of chronic diseases and imposes substantial economic costs on societies.

Not surprisingly, the promise of these new drugs has also brought excitement to equity investors. Who really wins and loses from a “miracle” drug that provides a wholesale cut to calorie consumption by way of appetite suppression? In today’s Note, our Q&A addresses key considerations for sustainability-minded investors by exploring the viability of anti-obesity drugs and their potential implications for food stocks.  

Question #1: What are these new weight-loss drugs?

The story of GLP-1 receptor agonists – the scientific descriptor for obesity drugs like Ozempic and Wegovy – is a fascinating tale of scientific curiosity, serendipity, and perseverance. In the 1990s, a group of scientists at Novo Nordisk were studying the venom of the Gila monster, a lizard native to the southwestern U.S. They were interested in the venom’s ability to lower blood sugar levels and discovered that the venom contained a hormone with similar structure to glucagon-like peptide-1 (GLP-1), the now famous naturally occurring hormone that stimulates insulin secretion. A first GLP-1 receptor agonist, Exenatide, was approved in 2004 for treatment of type 2 diabetes. But the real revolution happened during the clinical trials in 2017 for another GLP-1 receptor agonist, the infamous Ozempic, when participants with obesity who received Ozempic lost an average of 15% of their body weight, compared to just 2.4% for those who received a placebo. The weight loss results from this diabetes drug were so impressive that Wegovy, a higher-dose version of Ozempic, was approved by the FDA for the treatment of obesity in 2021.

While Novo Nordisk was first and continues to dominate the market, other Big Pharma players are not letting this massive opportunity slide. Eli Lilly, Novo’s century-old rival in the insulin space, just got its own GLP-1 receptor agonist, Tirzepatide a.k.a. Mounjaro, approved for use as a weight loss treatment under the name Zepbound by both US and UK regulators last week. In total, there are about 8 to 10 other GLP-1 receptor agonists currently approved for diabetes but with known weight loss co-benefits that could eventually be approved for obesity, which would significantly improve the competitive landscape.

Question #2: Why is this a sustainability issue?

Obesity is a major public health concern, contributing significantly to the burden of chronic diseases and imposing substantial economic costs. Estimates indicate that obesity accounts for a staggering $1.72 trillion in direct and indirect health care expenditures in the United States, representing a hefty 9.3% of the nation's current gross domestic product (GDP) – a number that should increase to 14% in the next decade according to the OECD.

 

The staggering costs associated with obesity underscore the urgent need for effective prevention and treatment strategies. Addressing the obesity epidemic requires a multi-pronged approach that encompasses lifestyle interventions, public health policies, and accessible treatment options – like GLP-1 receptor agonists.

As we will see later in this note, these drugs are not cheap! Access to effective obesity treatment drugs is often determined by an individual's socioeconomic status. Individuals with lower incomes may face difficulties affording these medications, putting them at a disadvantage in managing their weight and improving their overall health. This could lead to a widening gap between the health outcomes of affluent and disadvantaged populations.

Moreover, the high cost of these drugs could exacerbate existing disparities in healthcare access. Individuals without adequate health insurance or with limited financial resources may be unable to access these treatments, further hindering their ability to address their weight-related health concerns.

Question #3: What is the role of insurance in getting these medicines to a wider public?

Priced between $10,000-18,000 per year, these drugs pose a financial hurdle for individuals without insurance coverage. Considering the (alarming) obesity prevalence of 40% in the U.S. population, a substantial number of people may require or desire these medications.

With 9% of the population being uninsured, public insurance plays an instrumental role through programs like Medicare and Medicaid. Medicare provides prescription drug coverage to nearly 50 million Americans but does not currently cover weight loss medications because it considers them as "lifestyle enhancers", the same as gym costs.

There has been pressure to account for weight as a health issue rather than a cosmetic one. Obesity was classified as a disease by the American Medical Association in 2013. However, efforts to pass a Treat and Reduce Obesity Act which would cover medications for obesity covered through Medicare have been unsuccessful.

Under Medicare, 20% of people are diagnosed with obesity. The New England Journal of Medicine estimates that if 10% of these diagnosed individuals opted for a weight loss drug, it would consume nearly 10% of the Medicare’s total budget. This financial strain highlights the delicate balance that public insurers face between the potential long-term benefits and the substantial cost of covering weight loss drugs. Private insurers also appear hesitant to include these medications in their coverage.

At the current price, cost benefits of the drug remain unclear. A 2022 study by the Institute for Clinical Economic Review estimated a maximum annual cost $3818 below the annual price tag for Wegovy to be considered cost effective. Going forward, a restrictive approach appears likely, mirroring recent cases such as the Alzheimer's medication Aduhelm.

Question #4: What are the prospects for equity investments in Eli Lilly and/or Novo Nordisk?

The emergence of weight loss drugs like Eli Lilly's Mounjaro and Novo Nordisk's Ozempic marks a strategic shift for these pharmaceutical giants. Eli Lilly and Novo Nordisk's revenue are heavily concentrated in diabetes and obesity care drugs.

The graphs below highlight the expected growth that semaglutide drugs like Wegovy and Ozempic are expected to bring to Novo Nordisk. Sales forecasts anticipate that 65% of Novo Nordisk revenues will come from those obesity/diabetes drugs. A similar compound, tirzepatide, is expected to have a parallel effect for Eli Lilly, going from close to nothing to more than 40% of sales in 2025. Earnings growth is expected to follow a similar path. Both stocks are priced for rapid adoption, demand currently exceeds supply for these drugs and both companies enjoy tremendous pricing power. Price to earnings ratios are very high, reflecting anticipated strong growth based on relatively optimistic expectations.

 

What could go wrong? One might recall Fen-Phen from the 1990s - another weight-loss drug that worked by suppressing appetite. The drug had significant hype but was eventually recalled for serious side effects affecting the heart. GLPs might be less at risk as they have been used in the treatment of diabetes for at least two years now, but such examples should not be ignored.

Indeed, the current list of side effects is long (constipation, diarrhea, nausea, vomiting, headache, abdominal pain, fatigue, low blood sugar, vision changes pancreatitis, kidney failure, gallbladder issues and allergic reaction). There is also risk for thyroid cancer. Moreover, once patients stop getting injections, they generally gain back most of their weight, which could be an issue for wider adoption, i.e. could become a deterrent to new users. In sum, these drugs are a massive development, but investors should be aware that some of the hype will not materialize, especially if prices stay elevated.

A recent poll found that despite much interest in weight loss drugs, only 16% of respondents would be willing to pay out of pocket. Whether insurers cover these drugs will have a significant impact on their uptake.

Drugmakers will no doubt lobby heavily for insurance coverage and high cost is the biggest contention point for insurers. An expensive drug that a large share of the population would qualify for, for their lifetime, means significantly higher costs. While insurers do access lower prices through rebates negotiated by Pharmacy Benefit Managers, given their smaller number of insured, private insurer’s power to negotiate drug prices is weaker than the government’s.

Overall, the path to insurance coverage remains uncertain. If approved, it is likely to be accompanied by high copayments or with specific requirements such that not everyone who is obese would qualify. Limited insurance coverage for such expensive drugs could be an important hurdle to their sales growth.

Question #5: These medications act as appetite suppressants, leading many analysts to the conclusion that food companies will suffer via a loss of sales. Just how many calories are we talking about?

The largest – but certainly not the only – market for obesity drugs is the U.S. Currently, about 1.7% of Americans have been prescribed an anti-obesity medication. This number is expected to grow; Morgan Stanley estimates that in a decade, about 24 million Americans, representing 7% of the total U.S. population, will be taking a weight loss drug.

We have performed back-of-envelope calculations to understand what implications this could possibly have on the food industry using pertinent facts and necessary assumptions below: 

Using this information, we calculate that even in an ambitious scenario whereby 24 million Americans are taking a weight loss drug, the drop in total fast-food revenues is around 1% annually.

Question #6: What has been the equity market reaction so far and what should investors expect going forward?

The GLP-1 space got a one-two punch in August: Novo Nordisk released a study showing that their drug helps patients lose weight and lowers the risk of cardiovascular events, while Eli Lily earnings showed explosive demand for their drug. The equity market has since priced in robust demand for these drugs, sending their producers’ share price higher. On the flip side, investors have extrapolated that less calories being consumed will start to eat (pun intended) into the sales of snack food makers and fast-food restaurants. In October, Walmart released data showing that customers that bought Ozempic were buying less food: causing a major leg down in share price on the already weak snack food sector. As much as we are happy to see unhealthy snack companies’ share price fall, it looks like the sector is oversold on an absolute and relative basis. Similarly, given our above calculations regarding only a small potential sales loss at fast food outlets, fast food retailing stocks should not be severely negatively impacted.

The Tech Titans

In last week’s note (“The Apple Case Study: Magnificent and Sustainable?”, November 2, 2023) we delved into the sustainability efforts of Apple. This week, we turn our attention to the other giants in the “Magnificent 7”. We examine their robust performance and discuss implications for investors focused on sustainability.

The evolution from “FAANG” (Facebook, Apple, Amazon, Netflix, Google) to the Magnificent 7 (encompassing Microsoft, Nvidia, and Tesla in addition to FAANG but excluding Netflix) highlights the relentless expansion and market hegemony of these tech giants. In the current year, the Mag 7 has not just led the market but have significantly outpaced the S&P 500.

Indeed, not owning this group of companies in 2023 has been detrimental to many investors: these seven stocks are outperforming the benchmark by a wide margin. Year-to-date, virtually all the gains in the S&P 500 Index can be attributed to the Mag 7, and their weight in the index has reached all-time highs. This has been a big headache for active managers.  

The Hype

The impressive growth trajectory of the Mag 7 has been fueled by exposure to artificial intelligence (AI) and cloud computing, areas experiencing explosive growth. Despite pressure from rising bond yields on tech stocks’ long duration and their steep valuations compared to the equity benchmarks, money continues to chase their share price higher. The Mag 7 has also been boosted by financial market participants’ pricing of a soft landing and benefit from passive flows that buy the benchmark. Their outsized impact on the market indices and investment portfolios presents a complex scenario: the Mag 7 serves as both a propeller of growth and a potential amplifier of systemic risk because of their sheer market weight. Furthermore, there is an extra layer of complexity as the sheer size of these companies brings greater scrutiny and greater regulatory risks.

Navigating Legal Waters

As pioneers in innovation, the Mag 7 tech stocks are increasingly encountering legal challenges. The volume and nature of litigation these companies face is reflective of their operational scale, and their aggressive pursuit of market share through anti-competitive behavior. Patent disputes are common, often stemming from the high-stakes race to secure intellectual property rights. President Biden's administration is intensifying scrutiny on monopolistic practices, resulting in a proliferation of antitrust and competition-related legal actions. This is mirrored in the uptrend of legal cases for some companies since 2021 (see chart below).

The prevalence of patent and antitrust lawsuits of the Mag 7 bear significant implications. The risks include potential financial liabilities and also risks to reputation, regulatory compliance, and business models.

Meta, Amazon, and Alphabet have seen the greatest increase in the number of litigations in the past few years. Specific examples for each company are described below:

Meta: Meta is facing lawsuits from 41 states, claiming the company's social media platforms, particularly Instagram and Facebook, are addictive and harm children's mental health. Consequences for Meta may include the implementation of stringent age verification systems, modified content algorithms to reduce addictive tendencies, and clear labeling of digital health risks. Such reforms could diminish user engagement and advertising revenue, directly affecting stock valuation.

Amazon: Amazon is accused of using a secret pricing algorithm ("Project Nessie") to inflate prices, with the FTC lawsuit suggesting the company earned over $1 billion from this practice. A ruling against the company could result in orders to dismantle or significantly alter its pricing algorithms, increased regulatory oversight, and compensation for affected customers. For Amazon, this could lead to lower profit margins, a loss of competitive advantage, and a decrease in market share.

Alphabet: Alphabet is under scrutiny for antitrust issues, with the DOJ filing a lawsuit over its advertising and search engine practices. If Alphabet is found to have violated antitrust laws with its advertising and search practices, the company could be required to separate parts of its advertising business and alter its search algorithm to ensure fairer competition – akin to what happened to Microsoft in 2000. The implications for Alphabet may involve a reconfiguration of its core business model and a decrease in ad revenue growth. For shareholders, the risks are tied to potential drops in share price and future earnings, coupled with the uncertainty of Alphabet’s strategic direction in a more regulated environment.

Investors must consider the potential for substantial regulatory shifts and financial penalties that could impact the operations and valuations of these tech giants. Furthermore, these issues bring into question the place of these companies in sustainability funds.

Sustainability: Seeing Through the Haze

The technology giants have a noteworthy presence in sustainable investment funds. The Mag 7 stocks are prominently featured in funds adhering to the Sustainable Finance Disclosure Regulation (SFDR) Articles 8 and 9 as depicted in the following table:

However, using a double materiality approach, i.e. one that considers both the operational performance and the impact the companies’ products and services have on the planet and its people, we uncover a different conclusion. The broad inclusion of these stocks in sustainability-focused funds may be somewhat dubious.

According to our double materiality analysis, Microsoft and Nvidia emerge as leaders compared to their Magnificent 7 peers. They show positive alignment with sustainability both operationally and through their products and services. Conversely, Amazon and Meta display significant challenges, warranting caution for investors seeking to prioritize sustainability. Apple, Alphabet, and Tesla present a mixed landscape, with commendable initiatives overshadowed by areas of concern (see the Apple case study note from November 02, 2023, for a detailed breakdown of Apple).

What Should a Sustainable Investor Do?

Based on the above analysis, a sustainable investor’s choices in the Mag 7 are somewhat slim, even before considering what the extremely lofty valuations of these companies (see table below). Amazon and Meta are not appropriate as long positions in a sustainable strategy. For investors that hold companies that we view as neutral regarding sustainability (Tesla, Apple and Alphabet), only Alphabet looks interesting based on its growth expectations relative to forward P/E. Telsa’s high P/E isn’t justified by its growth expectations, while Apple is not growing at all, failing to justify its premium valuation over the market. As for the only two companies of the Mag 7 that we do view as sustainable: Microsoft looks like the safer bet as it still has many avenues to continue growing. Nvidia is trading on a lot of AI hype, and we don’t believe that its growth expectations will be able to be met. For investors that can short sell, an interesting pair trade would be to buy Microsoft and short Amazon: both have been growing in cloud computing, but Microsoft has the added AI potential, while Amazon has the negative of slower consumer spending and regulation overhang.

The past decade has witnessed remarkable progress in access to financial services around the world. Technological developments led to a growing number of FinTech platforms that enabled a greater number of poorly-served people to access financial services. New service providers increased competition for several different platforms – bank transfers, electronic payments, cell phones, etc. – in countries where such choices are available. These developments were useful to 1) empower consumers; 2) extend the reach of financial services to a greater share of the population; and 3) lower transaction costs. Today, the most underserved individuals with regard to access to financial services are found in Asia and Sub-Saharan Africa.

Despite this progress, it is still challenging to qualify the extent to which companies in the financial sector can have an “impact”. At Sustainable Market Strategies, we designed a matrix that shows the many ways a financial company can have impact according to the services they provide in developed, developing and frontier markets.

From our perspective, financial companies who “push the envelope” and look to increase their reach by growing their exposure to the underserved are considered impactful. For example, the penetration rate of mobile money services in regions such as Sub-Saharan Africa is a testament to the impact of such services on those populations. Airtel Africa is an example of a Telecom company which provides a fair amount of financial services to its client base.

In developed markets, financial companies can typically be considered impactful if they provide services to lower-income “unbanked” and/or “underbanked” populations. For their part, insurance companies who establish methods to limit price increases of their premiums and ensure coverage in higher-risk areas (i.e. areas with higher crime rates, lower incomes, and greater climate risks) would be considered impactful. This is especially relevant in the U.S. where a growing number of people are going uninsured.

 

In emerging and frontier markets, banks with specific outreach programs such as microfinance business streams and/or payment/transfer/mobile phone companies that facilitate the availability of services via digital platforms are considered impactful because of their contribution in elevating people out of poverty. Additionally, financial companies that facilitate and/or lower the costs of P2P transfers between DMs and EMs/FMs are also considered impactful as the provision of low-cost international transfer services could enable greater financial flows from DMs towards EMs and FMs.

 

In today’s note, we look at three investment ideas whereby investors looking to have an impact can invest in the financial sector: Community Banks, EM/FM banks and transfer payment providers. This note builds on our previous analysis of the financial sector (see our note “Three (Sexy) Banking Plays to Change the World” September 8, 2022).

Idea #1: DMs/US Community Banks

Community banks typically cater to regional communities across the United States. With their loan portfolio and deposit base “close to home”, these institutions are often very familiar with the people they serve and their regional markets. That said, recent wobbles in the U.S. banking system and the more stringent funding requirements have hit this sector hard. Furthermore, many communities and regional banks have a relatively high exposure to commercial real estate – which remains itself under stress as the asset class continues to re-price. Thus, it is not surprising that U.S. community banks have underperformed the overall sector in the U.S. – and globally – over the past year. 

It is difficult to see a good entry point into U.S. community banks at this juncture. After all, persistently high interest rates should continue to create problems in their loan portfolios as well as challenge their asset and liability matching over the next few months.

Idea #2: EMs/FMs Banks

To have in impact, one could also consider investing in EMs/FMs banks that are leading the pack with regard to financial inclusion. While country-level data on financial inclusion is made available by organisations such as the WorldBank or the IMF, bank-level data on financial inclusion remains scarce. That said, sustainably-minded investors looking to invest in financial institutions with a view to promote financial inclusiveness could look into some data published by the World Bank, as highlighted in the table below.

With this in mind, EMs/FMs banks really ought to disclose more data on financial inclusion as a means to grow their investors’ base. Looking at recent pricing trends in global banking stocks, one can see that banks have underperformed the global equity market these past few months – especially EM banks. While interest rates have not “normalized” as much in EMs as they have may have done in DMs, one can think that (in absence of issues around financial stability and excluding Chinese banks) higher-for-longer interest rates could help EM banks boost their net interest margins in the coming months. This should contribute positively to their profit margins going forward.

Finally, we look at financial inclusiveness mentions in Financials’ sector filings included in the MSCI FM and EM indices. Interestingly, mentions of financial inclusion are about absent in U.S. banks filings. Aside from financial institutions such as VISA, it is hard to believe that U.S. financial institutions – such as Goldman Sachs or BlackRock – are really putting financial inclusion high up on their agenda.

Conversely, mentions of financial inclusiveness are much more prevalent in EM and FM financial insitutions’ filings.

This seems especially true for institutions such as the Commercial International Bank (Egypt) and Creditcorp (Peru), two frontier markets’ banks. Interestingly, both have outperformed the MSCI Frontier index this past year and for investors ready to look for financial inclusiveness plays on the margins – these institutions could prove a smart way to address financial inclusiveness through publicly-listed banks in the frontier space.

Idea #3: Transfer payment companies

Recent developments in FinTech and the strong growth of the global market for remittances gave a boost to transfer payments companies – especially those looking to shave off costs on international money transfers. A recent compilation of newcomers in the transfer payment market suggests that these firms’ markup on international transfers varies from 0 to 1.5%. This compares to about 1-6% using the mid-market FX rate for a traditional transfer company such as Western Union. As a result, the market for global remittances has gotten much more competitive – and this comes to the benefit of users of such platforms.

From an impact perspective, one could favor transfer payment companies that offer the possibility to do P2P transfers from DMs to EMs at a lower cost. While companies like Western Union provide the biggest outreach in the remotest part of the planet – they are also the most expensive service in the sector. Conversely, upcomers such as Wise payments, which enables transfers to a wide range of geographies and currencies – offer discount transfer and FX rates and are quickly gaining market share as their service is offered in an increasing number of currencies. For its part, Remitly offers the possibility to send and receive money transfers – but just for users in the U.S. at this point – which makes it less interesting from an impact perspective. Despite the sector’s tailwinds coming from the growing global remittance markets and low-cost international financial transfers, these companies have underperformed the NASDAQ over the past year – aside for Remitly and Wise. Interestingly, some money transfer companies display hefty profit margins, hovering around 20%, which could make an interesting investment opportunity.

Looking at valuation, newcomers appear expensive against more established players. No doubt that market participants are pricing an outcome whereby lower-cost alternatives such as Wise, Remitly and others rapidly displace “old school” companies such as Western Union.

 

You may remember Miss Materiality from our December note: Miss Materiality’s Night Out: A Lesson in Consumer Choice. She is back again this week, and in search of summer vacation plans that meet her budget and reflect her values.

Consumers don’t seem to be holding back on lavish spending despite the economic backdrop of higher interest rates and high inflation. Economists have even attributed Beyonce and Taylor Swift concert goers with boosting economic activity in some regions. When Miss Materiality looks at the price for those concerts, hotels and airline tickets, she wonders, “how can they afford this ?!”.

Inflation data for June showed that prices for hotels and restaurants remain well above pre-pandemic levels, though airfares have cooled recently, experiencing an 8% drop from May to June. The latter could be a sign of consumers’ last hurrah with pandemic revenge travel as a more dire economic reality is setting in.

Miss Materiality is also concerned by recent climate news. Just as the pandemic had disruptive effects on tourism-dependent industries, she wonders how the realities of rising global temperatures will shape the future of travel. This reflection has made her more cognizant of how her travel choices impact her carbon footprint and the climate.

Still, Miss Materiality wants to do something during her time off. To settle on her vacation plans, she will need to choose her destination, accommodation, and transportation with consideration for both her budget and the environmental and social impacts from her spending choices.

 

Destination

Miss Materiality is relieved she didn’t travel to Europe during July where record temperatures and historic wildfires left some destinations looking more apocalyptic than dream vacations. The continent’s record hot summer last year was already enough for travellers to seek cooler places for their 2023 vacations: Travel operator Black Tomato reported a 37% increase in bookings for Scandinavia compared to 2022 and Spanish travel booking site EDreams Odigeo saw a significant increase in searches for destinations further north, notably Ireland for which searches were up 1000%. Miss Materiality will do the same, opting for a location where she can avoid the worst of the heat. As climate records continue to be broken, she can’t help but wonder whether mother nature will get the last word and if some of the most popular tourist spots have hit peak travel forever.

Miss Materiality considers visiting New Zealand where it is currently winter. The country is known for its beautiful landscapes and is hosting the 2023 Women’s World Cup during August. However, the long flight equates to a lot of emissions, and despite her passion for the sport, Miss Materiality has her qualms with FIFA.

She looks a little closer to home; beautiful British Columbia (literally the province’s tagline) where the Rocky Mountain range offers plenty of hiking opportunities. Though cooler than southern Europe, she learns the province is also experiencing intense wildfires. She doesn’t want to chance it. She’ll have to keep searching.

 

Accommodation

Perhaps finding the right hotel will help narrow her search. She looks for hotel chains with locations in more temperate regions. If the statistics above are any indication, such locations will benefit from rising demand over the next few years, and she can say she was there first!

The hospitality industry is a labor intensive one. In the U.S., the Leisure and Hospitality industry currently accounts for 11% of the workforce.

With a substantial number of people relying on the industry for their employment, metrics like employee compensation, benefits and working conditions are part of Miss Materiality’s criteria when evaluating hotels that align with her values. Companies that treat their employees right will benefit from lower turnover rates and cost savings from training new personnel. This is especially true when there is a labor shortage, as evidenced by wage data from the past three years (see chart below). To attract and retain talent following the pandemic, compensation in leisure and hospitality has outpaced overall wage growth, and the other consumer discretionary industry of retail. The dynamic has been similar in Europe. After all, a hotel is unlikely to get return customers if the service is not up to snuff.

Miss Materiality knows that effective energy and water management is relevant for addressing hotels’ environmental impact. She also looks for sustainability certifications like LEED and the Green Key Eco Rating. The table below shows five hotel companies that align with Miss Materiality’s environment and labor criteria as well as locations in cooler regions.

Even if she doesn’t end up staying at one of these hotels, she can consider adding them to her investment portfolio (also sustainability focused) when the economic context is more conducive.

 

Transport

Often the greatest contributor to an individual’s carbon footprint, transport is the most difficult consideration for Miss Materiality’s travel plans.

Growing awareness of the emissions and pollution from travel is beginning to drive some policy changes.

France’s ban on short-haul flights and the Netherlands’ restrictions on flights to Amsterdam and closure of cruise ship terminals show shifting attitudes. New measures proposed by the European Emissions Trading System and the International Maritime Organization (IMO) to charge shipping companies for their CO2 emissions could have substantial implications for cruise ship operators’ bottom lines.

Miss Materiality welcomes these actions; particularly when it comes to cruise ships. For indecisive travel planners, cruise ships may seem like an easy choice with multiple destinations, accommodation and transport bundled into a single package. However, the reality behind this convenience is that cruise lines are notorious polluters. Per kilometre emissions are estimated to be worse than taking the plane. Within marine transportation, cruise ships are the biggest emitters of black carbon (aka soot) and one European study in 2022 showed cruise ships emitted 4.4 times more sulphur oxides (SOx) than all the cars on the continent.

The regulatory risk faced by cruise operators is not reflected in their stock prices which have been inflated by robust bookings from Covid’s revenge travel. Between this and their unsustainable debt levels (Royal Caribbean, Carnival Corporation and Norwegian Cruise Line have debt to equity ratios of 624, 598 and 86198 respectively), Miss Materiality sees a short opportunity rather than a viable travel option.

As climate issues intensify, Miss Materiality anticipates tougher regulation on pollution and emissions stemming from travel. She believes this will support increased investment into more environmentally friendly modes of transportation like rail. For instance, America’s passenger rail system, Amtrak, is undergoing a $66 billion investment as part of the Infrastructure bill passed in 2021. Though North American passenger rail systems still mostly rely on diesel locomotives, taking the train instead of a flight is often the more ecological choice, especially for shorter inter city trips. Just earlier this week, France’s Transport Minister discussed plans to tax airlines in order to support investment in the country’s rail transit. Policies such as these should result in tailwinds for companies in passenger rail equipment, such as Westinghouse Air Brake Technologies, Siemens, and Alstom.

News earlier this summer about DoorDash now offering its delivery workers an hourly wage option caught our attention as the appeal to zoom through cities delivering via e-bike likely rises as summer sets in. This rather positive development occurred as many are arguing that the business model of app-based delivery companies remains dependent on shortchanging workers. A recent article about the life of gig-delivery workers in Toronto underlines the perils and low pay in the industry. After all, delivery workers – especially those who work for app-based companies – remain among a low pay group – with the highest quintile earning only about USD 23 per hour.

Perhaps more important than pay, data from the U.S. Bureau of Labor Statistics on work-related injuries shows that delivery workers have the 12th highest rate of injury in the whole economy – not that different from that or prison or iron workers (as a reminder, the incidence rate of injuries and illnesses is computed from the following formula: number of injuries and illnesses X 200,000) / Employee hours worked = Incidence rate).

The proliferation of delivery app workers and the fact that their pay can hardly be considered a ‘living wage” prompted some cities such as NYC to legislate a minimum wage in the industry – paid hourly – to the workers of these companies. Despite this, several accounts from workers suggest that their take-home pay – especially once one accounts for bike/car expenses – remains below that of legislated minimum wages and still offers little-to-no protection against work-related injuries. Some workers also report that more than 50% of their wages come from customer tips (which compares to about 25% in the restaurant industry); this makes total pay highly unstable.

Furthermore, many workers have also reported some level of wage compression in the industry these past few years, which coincides with the falling ratio of personnel expenses as a percentage of sales for app-based delivery companies since 2017. Conversely, UPS, a parcel company well known for its above-average pay packages, displayed a flat ratio during the same period. This suggests that some app-based companies are increasingly squeezing their deliverers – notably through the use of AI-based algorithms that favor the employer over the employee when allocating delivery routes.

Many workers in the delivery sector are recent immigrants. The contractual nature of their employment with app-based companies limits their integration and progress in the formal job market – while putting them at risk of injuries and/or legal pursuits when accidents occur. In this context, it is not surprising to see that poor compensation and benefits are recurring complaints against app-based companies on platforms such as Glassdoor, a website which reviews employee satisfaction with their employers.

Despite a business model highly dependent on unfair labor practices, app-based delivery companies displayed strong revenue growth in the past few years – while remaining unprofitable. Some companies such as Delivery Hero also display high debt-to-equity ratios, negative 3Y EPS growth and negative profit margins, suggestive of a fragile financial structure being built atop an increasingly fragile cheap labor model.

Many-pure-play delivery companies’ market capitalization is less than half what it was in 2019. One exception is UBER, which is more a play on mobility (and not without its own set of labor and regulatory issues) than a play on food delivery through its “Eats” delivery platform continues to display the strongest fundamentals in the sector and performed on par with the MSCI World since 2019.


Looking at historical profit margins, one sees that a company such as DoorDash has failed to deliver a positive profit since it IPO’d in 2020.

A final consideration is that the price markup associated to getting your food delivered to your door does not make any sense in a context of already high inflation. A recent comparison (2022) of markup margins for Canadian delivery app users suggests that prices can be marked up by as much as 50 percent by such platforms.

The global population is aging, with the situation being particularly acute for high-income nations (as defined by the World Bank) where the share of the population over 65 years of age is expected to be around 26% by 2041 according to latest UN population estimates (comparably, the projected global share is 14.7%). With this demographic shift, specialized devices and equipment that cater to the needs of older adults will experience a surge in demand.

A year ago, we explored the broad sector of healthcare in our note “High Impact: Surviving a Recession with Care“, (June 2, 2022). In this week’s note, we focus on medical equipment designed to enhance longevity of older individuals. We consider two distinct categories of devices: those enhancing wellbeing and quality of life, and those that directly prolong life through the treatment of non-communicable diseases. The first category encompasses devices used to restore mobility, hearing and sight, such as hip replacements, hearing aids and intraocular lenses. The second category includes devices and equipment used in the management of chronic conditions associated with common non-communicable diseases such as cardiovascular disease, cancer, neurological disorders, and respiratory illness.

Enhanced Wellbeing and Quality of Life

Although joint replacements, cataract surgeries and hearing aids are known as elective procedures since patients can technically live without them, they nonetheless contribute to patient longevity by significantly improving overall quality of life. Consequently, these procedures are often covered under public health plans or deemed worthwhile investments for those opting for private health services.

With seniors being more prone to the issues of mobility, vision and hearing loss, demand for associated devices is expected to increase as seniors’ share of the population grows. We can see this trend in the chart below. In the decade leading up to the pandemic, the number of knee and hip replacements in reporting G7 countries was steadily increasing. The combined total of hip and knee replacement surgeries increased 24.1% while the proportion of citizens between the ages of 60 and 70 for the corresponding countries increased 15.9% over the same time horizon.

Unsurprisingly, 2020 (the latest year for which this data is available) saw a significant decline in joint replacement surgeries, but comments made last week by executives at insurance companies UnitedHealth and Humana suggest a rebound in joint replacement procedures is underway. This could result in a boost to earnings at the next reporting date for companies that produce orthopedic implants. The top companies by revenue that are specialized in orthopedic devices include Zimmer Biomet (67% of revenues in joint replacement devices), Stryker Corp (28%) and Smith & Nephew (68%). Stryker has been the top performer, though all three have outperformed the SP Health Care Sector in the past year.

Relative to other categories in this note, companies providing equipment for the visually impaired have high valuations collectively. Similarly, providers of hearing aid solutions have recently rallied, so it may be wise for investors to wait for a better entry point when it comes to vision and hearing devices. Companies like Alcon, Hoya and Carl Zeiss offer lenses for the treatment of cataracts, among other things, but have P/E ratios over 30. Hoya, a Japanese company, has diversified revenues through exposure to the semiconductor industry as a provider of manufacturing equipment (28% of revenues). This makes for an interesting opportunity given the current tailwinds in both Japan and AI. The main providers of hearing solutions include Sonova, Cochlear and Demant.

 

Diagnoses and Treatment of Non-communicable Diseases

Globally, non-communicable diseases (NCDs), such as cancer and heart disease, are responsible for 74% of all deaths. Even within G7 countries where treatment is more accessible, 89.5% of deaths of individuals over the age of 70 were attributed to NCDs in 2019. The NCDs most frequently resulting in death for seniors aged 70 and up are cardiovascular diseases, cancers, chronic respiratory diseases and neurological conditions such as Alzheimer’s and Parkinson’s. For these health issues, access to adequate treatment is directly linked to longevity.

Investment in innovative companies dedicated to finding cures to NCDs offers the potential for significant impact. However, predicting the winners and timing for such discoveries is a challenge. Alternatively, recent advances in the medical equipment used for diagnosing or treating these diseases are providing positive outcomes helping to extend patients’ lives. Therefore, opportunities in treatment and diagnostics still make for an impactful investment, one with more stable revenues and defensive characteristics. As the population ages, demand for both diagnostic testing and treatment will rise as a growing number of individuals begin to exhibit symptoms. Additionally, the prevalence of these diseases suggests an increase in preventive screenings which are often recommended based on age and family history.

Looking at the top 5 companies by revenue for diagnostic devices: all but one achieved strong sales growth over the past three years. Indeed, diagnostics from COVID testing may have provided a nice bump over this timeframe. However, with the exception of Roche holdings, each of Siemens Healthineers, Abbott Laboratories, Thermo Fisher and Danaher maintained positive sales growth for 2022 as COVID worries subsided.

Despite its weaker sales growth, Roche is an attractive opportunity. Roche has a lower valuation than its diagnostic device peers and earns the majority of its revenues from biopharmaceuticals (73%) with sizeable exposure to oncology treatments (30% of total revenues). As this segment should also experience long-term growth, Roche is well positioned in both diagnostics and treatment of NCDs.

GE Healthcare Technologies and Hologic are two other large healthcare equipment names that are relatively cheap for healthcare equipment providers, with P/E ratios at 13.8 and 12.3 respectively. GE provides radiology equipment used for various diagnoses and is executing its strategy for digital solutions. Hologic is differentiated by its focus on women’s health which furthers its impact appeal: it is well documented that women are underrepresented in healthcare research.    

For impact investors focused more on treatment of the four major NCDs, it is challenging to find investment opportunities in medical equipment treating cancer and neurological conditions. Roche, mentioned previously, does offer biopharmaceutical products for the treatment of cancers. Treatments for neurological disorders such as Alzheimer’s and Parkinson’s remain at early stages though companies like Biogen are making progress. Thus, it is currently cardiology devices that have the greatest potential for life-saving treatment of NCDs. In addition to its diagnostic segment, Abbott Laboratories is also a major player in devices for the treatment of cardiology issues. For more of a pure play in tackling heart disease, investors can look to Edward Life Sciences or Boston Scientific.